Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neur… Read more
Alzamend Neuro Inc (ALZN) - Net Assets
Latest net assets as of October 2025: $4.37 Million USD
Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has net assets worth $4.37 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.09 Million) and total liabilities ($717.49K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.37 Million |
| % of Total Assets | 85.91% |
| Annual Growth Rate | N/A |
| 5-Year Change | 97.13% |
| 10-Year Change | N/A |
| Growth Volatility | 247.16 |
Alzamend Neuro Inc - Net Assets Trend (2016–2025)
This chart illustrates how Alzamend Neuro Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alzamend Neuro Inc (2016–2025)
The table below shows the annual net assets of Alzamend Neuro Inc from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | $3.97 Million | +252.97% |
| 2024-04-30 | $-2.59 Million | -185.18% |
| 2023-04-30 | $3.05 Million | -77.19% |
| 2022-04-30 | $13.35 Million | +563.28% |
| 2021-04-30 | $2.01 Million | +144.97% |
| 2020-04-30 | $821.71K | +159.28% |
| 2019-04-30 | $316.92K | -86.34% |
| 2018-04-30 | $2.32 Million | +496.51% |
| 2017-04-30 | $-584.93K | -551720.75% |
| 2016-04-30 | $-106.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alzamend Neuro Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5852368500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $78.00 | 0.00% |
| Other Components | $62.50 Million | 1575.10% |
| Total Equity | $3.97 Million | 100.00% |
Alzamend Neuro Inc Competitors by Market Cap
The table below lists competitors of Alzamend Neuro Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dong Il Steel MFG Co Ltd
KO:002690
|
$7.05 Million |
|
XXLLD
PINK:XXLLD
|
$7.05 Million |
|
TechStore Berhad
KLSE:0343
|
$7.05 Million |
|
Krungthai Car Rent and Lease Public Company Limited
BK:KCAR
|
$7.05 Million |
|
Wesure Global Tech Ltd
TA:WESR
|
$7.05 Million |
|
Bucur SA
RO:BUCV
|
$7.05 Million |
|
Australian Silica Quartz Group Ltd
PINK:BXRDF
|
$7.05 Million |
|
Wilmington Capital Management Inc
TO:WCM-A
|
$7.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alzamend Neuro Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,594,185 to 3,968,222, a change of 6,562,407.
- Net loss of 4,514,853 reduced equity.
- New share issuances of 10,440,196 increased equity.
- Other factors increased equity by 637,064.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.51 Million | -113.78% |
| Share Issuances | $10.44 Million | +263.1% |
| Other Changes | $637.06K | +16.05% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Alzamend Neuro Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.21x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-04-30 | $0.00 | $1.86 | x |
| 2017-04-30 | $-27.42 | $1.86 | x |
| 2018-04-30 | $68.98 | $1.86 | x |
| 2019-04-30 | $7.27 | $1.86 | x |
| 2020-04-30 | $15.57 | $1.86 | x |
| 2021-04-30 | $37.40 | $1.86 | x |
| 2022-04-30 | $202.30 | $1.86 | x |
| 2023-04-30 | $42.16 | $1.86 | x |
| 2024-04-30 | $-34.51 | $1.86 | x |
| 2025-04-30 | $8.80 | $1.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alzamend Neuro Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -113.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-113.78%) is above the historical average (-305.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-69.45K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.51 Million |
| 2018 | -40.18% | 0.00% | 0.00x | 1.04x | $-1.16 Million |
| 2019 | -1534.32% | 0.00% | 0.00x | 4.74x | $-4.89 Million |
| 2020 | -535.02% | 0.00% | 0.00x | 2.21x | $-4.48 Million |
| 2021 | -250.73% | 0.00% | 0.00x | 1.45x | $-5.25 Million |
| 2022 | -92.59% | 0.00% | 0.00x | 1.09x | $-13.70 Million |
| 2023 | -488.52% | 0.00% | 0.00x | 1.94x | $-15.18 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.69 Million |
| 2025 | -113.78% | 0.00% | 0.00x | 1.16x | $-4.91 Million |
Industry Comparison
This section compares Alzamend Neuro Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alzamend Neuro Inc (ALZN) | $4.37 Million | 0.00% | 0.16x | $7.05 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |